How high is the blockade success rate of Bituve/Bikernoprenol Tablets? Clinical data and patient feedback

Biktarvy's blocking success rate, that is, its effectiveness in treating HIV-1 infection, was evaluated through clinical studies. Based on current clinical data, Bituva has demonstrated very high virological suppression success rates. Multiple clinical trials have shown that for treatment-naïve patients and patients who have achieved virological suppression, Bituvi can inhibit HIV virus replication to a large extent and maintain a low viral load.

In a key phase III clinical trial, the success rate of virological suppression in treatment-naïve patients reached over 90%. In these patients, HIV-1 RNA levels remained below 50 copies/mL after 48 weeks of treatment with BITOVIR, meaning the virus was almost completely suppressed. This data shows that Bituvi has a very high efficacy in treatment-naïve HIV patients, can effectively prevent viral replication, and help patients maintain stable virological suppression.

The success rate of blockade with Bituvir is also very high in patients who have achieved virological suppression on existing antiretroviral therapy. In these patients, Bituvir can successfully replace the original treatment regimen and maintain long-term virological suppression. This is particularly important for patients who need to change their medications. Bituvi provides a simple, safe and efficient alternative drug to help patients continue to control the virus without increasing the complexity of treatment.

Bitavi's high success rate is also related to its excellent drug resistance. Its ingredients Bictegravir, Emtricitabine and Tenofovir Alafenamide show a lower incidence of drug resistance mutations in most HIV patients, which ensures the effectiveness of Bituvir in long-term treatment. The lower incidence of drug-resistant mutations ensures that patients can maintain a high level of viral suppression while receiving treatment, reducing the risk of viral rebound.

Reference materials:https://www.biktarvy.com/